This is the authors' abstract. We don't add key points for this paper.
Herpes-mediated viral oncolysis alone is not sufficient to completely eradicate tumors. In this study we used a replication conditional, endostatin-expressing herpes simplex virus-1 mutant (HSV-Endo) in a murine lung cancer model. We hypothesized that the anti-angiogenic action of endostatin would improve upon the oncolytic effect of HSV-1. HSV-Endo was evaluated in a pulmonary metastases and orthotopic flank model, where there was significantly less tumor burden and reduced microvessel density compared to a control virus. Endostatin expression appears to improve the anti-tumor effect of HSV-1 in a lung cancer model.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Goodwin et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: